The clinicopathological significance of BUBR1 overexpression in hepatocellular carcinoma

Journal of Clinical Pathology

Volumn 62, Issue 11, 2009, Pages 1003-1008

  Liu, A W ^a   Cai, J ^a,b   Zhao, X L ^b   Xu, A M ^c   Fu, H Q ^a   Nian, H ^b   Zhang, S H ^b  

^a NANCHANG UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUB1 RELATED PROTEIN; HEPATITIS B SURFACE ANTIGEN; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR VOLUME; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; LIVER; LIVER NEOPLASMS; MALE; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 73349099718     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.066944     Document Type: Article

References (37)

1. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008;48:2047-63.
2. Wilkens L, Flemming P, Gebel M, et al. Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma. Proc Natl Acad Sci USA 2004;101:1309-14.
3. Dey P. Aneuploidy and malignancy: an unsolved equation. J Clin Pathol 2004;57:1245-9.
4. Masuda A, Takahashi T. Chromosome instability in human lung cancers: possible underlying mechanisms and potential consequences in the pathogenesis. Oncogene 2002;21:6884-97.
5. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5:773-85.
6. Rajagopalan H, Nowak MA, Vogelstein B, et al. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003;3:695-701.
7. Wassmann K, Benezra R. Mitotic checkpoints: from yeast to cancer. Curr Opin Genet Dev 2001;11:83-90.
8. Lampson MA, Kapoor TM. The human mitotic checkpoint protein BubR1 regulates chromosome-spindle attachments. Nat Cell Biol 2005;7:93-8.
9. Hanks S, Coleman K, Reid S, et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet 2004;36:1159-61.
10. Shin HJ, Baek KH, Jeon AH, et al. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell 2003;4:483-97.
11. Gupta A, Inaba S, Wong OK, et al. Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1. Oncogene 2003;22:7593-9.
12. Seike M, Gemma A, Hosoya Y, et al. The promoter region of the human BUBR1 gene and its expression analysis in lung cancer. Lung Cancer 2002;38:229-34.
13. Haruki N, Saito H, Harano T, et al. Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in human lung cancers. Cancer Lett 2001;162:201-5.
14. Tanaka K, Mohri Y, Ohi M, et al. Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol) 2008;20:639-46.
15. Grabsch H, Takeno S, Parsons WJ, et al. Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer-association with tumour cell proliferation. J Pathol 2003;200:16-22.
16. Shichiri M, Yoshinaga K, Hisatomi H, et al. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res 2002;62:13-17.
17. Pinto M, Vieira J, Ribeiro FR, et al. Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. Cell Oncol 2008;30:389-95.
18. Ouyang B, Knauf JA, Ain K, et al. Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1. Clin Endocrinol (Oxf) 2002;56:341-50.
19. Wada N, Yoshida A, Miyagi Y, et al. Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature. Anticancer Res 2008;28:139-44.
20. Yamamoto Y, Matsuyama H, Chochi Y, et al. Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer. Cancer Genet Cytogenet 2007;174:42-7.
21. Saeki A, Tamura S, Ito N, et al. Frequent impairment of the spindle assembly checkpoint in hepatocellular carcinoma. Cancer 2002;94:2047-54.
22. Zhang SH, Xu AM, Chen XF, et al. Clinicopathologic significance of mitotic arrest defective protein 2 overexpression in hepatocellular carcinoma. Hum Pathol 2008;39:1827-34.
23. Tao X, Zheng JM, Xu AM, et al. Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma. Hepatol Res 2007;37:820-7.
24. Hamilton S, Aaltonen L. World Health Organization classification of tumours: pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000:167-9.
25. Wanless IR. International consensus on histologic diagnosis of early hepatocellular neoplasia. Hepatol Res 2007;37(2 Suppl):S139-41.
26. Xian ZH, Zhang SH, Cong WM, et al. Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma. Mod Pathol 2006;19:280-6.
27. Ma S, Guan XY, Lee TK, Chan KW. Clinicopathological significance of missing in metastasis B expression in hepatocellular carcinoma. Hum Pathol 2007;38:1201-6.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
29. Liang JJ, Wang H, Rashid A, et al. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res 2008;14:7043-9.
30. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005;2:416-22.
31. Pineau P, Marchio A, Battiston C, et al. Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res 2008;653:6-13.
32. Nakajima T, Moriguchi M, Mitsumoto Y, et al. Centrosome aberration accompanied with p53 mutation can induce genetic instability in hepatocellular carcinoma. Mod Pathol 2004;17:722-7.
33. Oikawa T, Okuda M, Ma Z, et al. Transcriptional control of BubR1 by p53 and suppression of centrosome amplification by BubR1. Mol Cell Biol 2005;25:4046-61.
34. Ha GH, Baek KH, Kim HS, et al. p53 activation in response to mitotic spindle damage requires signaling via BubR1-mediated phosphorylation. Cancer Res 2007;67:7155-64.
35. Burum-Auensen E, Deangelis PM, Schjolberg AR, et al. Spindle proteins Aurora A and BUB1B, but not Mad2, are aberrantly expressed in dysplastic mucosa of patients with longstanding ulcerative colitis. J Clin Pathol 2007;60:1403-8.
36. Yoon YJ, Chang HY, Ahn SH, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008;29:1192-6.
37. Kim S, Park SY, Yong H, et al. HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint. Oncogene 2008;27:3457-64.